PE123199A1 - Prostaglandinas tetrahidro sustituidas aromaticas c16-c20 utiles como agonistas fp - Google Patents

Prostaglandinas tetrahidro sustituidas aromaticas c16-c20 utiles como agonistas fp

Info

Publication number
PE123199A1
PE123199A1 PE1998000845A PE00084598A PE123199A1 PE 123199 A1 PE123199 A1 PE 123199A1 PE 1998000845 A PE1998000845 A PE 1998000845A PE 00084598 A PE00084598 A PE 00084598A PE 123199 A1 PE123199 A1 PE 123199A1
Authority
PE
Peru
Prior art keywords
alkyl
carbociclo
heteroalkyl
agonists
aromatic substituted
Prior art date
Application number
PE1998000845A
Other languages
English (en)
Inventor
John August Wos
Biswanath De
Jack S Amburgey
Haiyan George Dai
Mitchell Anthony Delong
Cynthia J Miley
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PE123199A1 publication Critical patent/PE123199A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I; DONDE R1 ES CO2H, C(O)NHOH, CO2R5, CH2OH, S(O)2R5, ENTRE OTROS; R5 ES ALQUILO, HETEROALQUILO, CARBOCICLO, ENTRE OTROS; R2 ES H o ALQUILO; X ES NR6R7, OR8, SR9 SOR9, SO2R9, F; R6, R7 Y R8 SON H, ACILO, ALQUILO, HETEROALQUILO, ENTRE OTROS; R9 ES ALQUILO, HETEROALQUILO, CARBOCICLO, ENTRE OTROS; R3 Y R4 SON H, CH3, C2H5, OR10, OH; R3 Y R4 NO SON A LA VEZ OH; R10 ES ALQUILO, HETEROALQUILO, CARBOCICLO, ENTRE OTROS; Y ES (CH2)n; n ES 0-3; Z ES CARBOCICLO, HETEROCICLO, HETEROCICLO AROMATICO, ENTRE OTROS. UN COMPUESTO PREFERIDO ES 13,14-DIHIDRO-17-(2,4-DIFLUORFENILO)-17-TRINORPROSTAGLANDINA F1O METIL ESTER, ENTRE OTROS. EL COMPUESTO PUEDE SER UTIL PARA EL TRATAMIENTO DE UN TRASTORNO OSEO TAL COMO OSTEOPOROSIS CORTICOESTEROIDE INDUCIDA, OSTEOPOROSIS POSTMENOPAUSICA, OSTEOPENIA, FRACTURA DE HUESO, GLAUCOMA
PE1998000845A 1997-09-09 1998-09-08 Prostaglandinas tetrahidro sustituidas aromaticas c16-c20 utiles como agonistas fp PE123199A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5824697P 1997-09-09 1997-09-09

Publications (1)

Publication Number Publication Date
PE123199A1 true PE123199A1 (es) 2000-02-02

Family

ID=22015602

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000845A PE123199A1 (es) 1997-09-09 1998-09-08 Prostaglandinas tetrahidro sustituidas aromaticas c16-c20 utiles como agonistas fp

Country Status (23)

Country Link
US (1) US6107338A (es)
EP (1) EP1021402B1 (es)
JP (1) JP2001515883A (es)
KR (1) KR20010023837A (es)
CN (1) CN1269785A (es)
AR (1) AR017077A1 (es)
AT (1) ATE310721T1 (es)
AU (1) AU741014B2 (es)
BR (1) BR9811779A (es)
CA (1) CA2303763C (es)
CO (1) CO4970730A1 (es)
DE (1) DE69832513T2 (es)
ES (1) ES2253826T3 (es)
HU (1) HUP0004436A3 (es)
IL (1) IL134792A0 (es)
NO (1) NO20001142L (es)
NZ (1) NZ503736A (es)
PE (1) PE123199A1 (es)
PL (1) PL339213A1 (es)
SK (1) SK3362000A3 (es)
TR (1) TR200000670T2 (es)
WO (1) WO1999012896A1 (es)
ZA (1) ZA988231B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015608A1 (en) * 1998-09-14 2000-03-23 Ono Pharmaceutical Co., Ltd. φ-SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
ES2232434T3 (es) * 1999-03-05 2005-06-01 Duke University Analogos de prostaglandinas c-16 fp selectivas insaturadas.
EP1202999B1 (en) * 1999-08-04 2003-06-18 The Procter & Gamble Company Novel 2-decarboxy-2-phosphinico prostaglandin f analogs
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US6376533B1 (en) * 2000-10-20 2002-04-23 Allergan Sales, Inc. Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
US6586462B2 (en) 2000-10-20 2003-07-01 Allergan, Inc. ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
US6531504B2 (en) * 2001-05-17 2003-03-11 Allergan, Inc. Prostanoic acid derivatives as agents for lowering intraocular pressure
US7631336B2 (en) 2004-07-30 2009-12-08 Broadband Itv, Inc. Method for converting, navigating and displaying video content uploaded from the internet to a digital TV video-on-demand platform
US7590997B2 (en) 2004-07-30 2009-09-15 Broadband Itv, Inc. System and method for managing, converting and displaying video content on a video-on-demand platform, including ads used for drill-down navigation and consumer-generated classified ads
US20060135609A1 (en) 2004-10-21 2006-06-22 Duke University Ophthamological drugs
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
AU2009340420A1 (en) 2008-10-29 2010-08-26 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
EP3053913B1 (en) 2009-05-01 2018-03-07 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
CA2850987C (en) 2011-10-17 2019-10-15 Biotheryx, Inc. Substituted biaryl alkyl amides
CN109528721B (zh) 2013-03-15 2021-10-01 爱瑞制药公司 联合治疗
CN104140410B (zh) * 2013-05-09 2017-12-15 江苏豪森药业集团有限公司 鲁比前列酮的制备方法
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
CA3035566A1 (en) 2016-08-31 2018-03-08 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
CN110506037A (zh) 2017-03-31 2019-11-26 爱瑞制药公司 芳基环丙基-氨基-异喹啉酰胺化合物
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4011262A (en) * 1972-07-13 1977-03-08 Pfizer Inc. 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins of the two series
IL43571A (en) * 1972-11-08 1977-08-31 Pfizer Omega-pentanorprostaglandins and their preparation
JPS5720305B2 (es) * 1973-02-28 1982-04-27
DE2365101A1 (de) * 1973-12-21 1975-07-10 Schering Ag Neue prostansaeurederivate und verfahren zu ihrer herstellung
DE2460990A1 (de) * 1974-12-21 1976-07-01 Hoechst Ag Neue prostaglandin-analoga und verfahren zu ihrer herstellung
DE2737808A1 (de) * 1976-08-27 1978-03-16 Pfizer 2-substituierte aryl-heterocyclische omega-pentanorprostaglandine
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
DE4024347A1 (de) * 1990-07-27 1992-01-30 Schering Ag Cyclopentanderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
US5545665A (en) * 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
US6169111B1 (en) * 1995-06-07 2001-01-02 Alcon Laboratories, Inc. Conformationally rigid aryl prostaglandins for use in glaucoma therapy
WO1997023225A1 (en) * 1995-12-22 1997-07-03 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
US5741810A (en) * 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
DE69714698T2 (de) * 1996-06-10 2002-12-05 Sucampo Ag Endothelin-antagonisten
DE69714274T3 (de) * 1996-09-17 2006-06-01 Asahi Glass Co., Ltd. Fluorierte prostaglandinderivate und medikamente
AU5436198A (en) * 1996-11-12 1998-06-03 Alcon Laboratories, Inc. 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
AU5258698A (en) * 1996-11-12 1998-06-03 Alcon Laboratories, Inc. 15-ketal prostaglandins for the treatment of glaucoma or ocular hypertension
AU725677B2 (en) * 1997-05-09 2000-10-19 Mount Sinai School Of Medicine Of The City University Of New York, The 8-iso-prostaglandins for glaucoma therapy

Also Published As

Publication number Publication date
AU9219498A (en) 1999-03-29
CA2303763A1 (en) 1999-03-18
EP1021402B1 (en) 2005-11-23
ES2253826T3 (es) 2006-06-01
IL134792A0 (en) 2001-04-30
WO1999012896A1 (en) 1999-03-18
DE69832513D1 (de) 2005-12-29
DE69832513T2 (de) 2006-07-13
NZ503736A (en) 2002-06-28
SK3362000A3 (en) 2000-10-09
CO4970730A1 (es) 2000-11-07
ZA988231B (en) 1999-03-09
TR200000670T2 (tr) 2000-11-21
NO20001142L (no) 2000-05-04
HUP0004436A3 (en) 2001-09-28
EP1021402A1 (en) 2000-07-26
US6107338A (en) 2000-08-22
KR20010023837A (ko) 2001-03-26
BR9811779A (pt) 2000-09-12
CN1269785A (zh) 2000-10-11
ATE310721T1 (de) 2005-12-15
AR017077A1 (es) 2001-08-22
AU741014B2 (en) 2001-11-22
CA2303763C (en) 2007-04-24
PL339213A1 (en) 2000-12-04
JP2001515883A (ja) 2001-09-25
NO20001142D0 (no) 2000-03-06
HUP0004436A2 (hu) 2001-05-28

Similar Documents

Publication Publication Date Title
PE123199A1 (es) Prostaglandinas tetrahidro sustituidas aromaticas c16-c20 utiles como agonistas fp
PE115499A1 (es) Prostaglandinas tetrahidro sustituidas aromaticas c16-c20 utiles como agonistas de la prostaglandina f (fp)
CO4910163A1 (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas
FI961506A (fi) Distamysiini A -analogit antituumorisina ja antiviraalisina aineina
DE59204623D1 (de) Lagerstabile, permanent wasserbenetzbare vulkanisate ergebende polysiloxanmasse.
BR0114630A (pt) Secretagogos de hormÈnio do crescimento
EA199800752A1 (ru) Пентафторбензолсульфонамиды и их аналоги
CL2004001168A1 (es) Compuestos analogos de camptotecina; procedimiento de preparacion de dichos compuestos; composiciones farmaceuticas que comprenden a dichos compuestos; compuestos intermediarios; y uso del compuesto en el tratamiento de tumores, una enfermedad virica
ES2111288T3 (es) Nuevos 3,4-diaril tiofenos y analogos de los mismos utiles como agentes antiinflamatorios.
TR200000673T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.
ES2192031T3 (es) Nuevas amidas aromaticas, su procedimiento de preparacion y su aplicacion como medicamentos.
ES2069424T3 (es) Metodos para el tratamiento de la osteoporosis.
BR8707408A (pt) Novos 5-alcoxi-2,4-diamino-alquibenzenos e composicoes de tingimento de cabelo com 5-alcoxi-2,4-diamino-alquil-benzenos
ATE30583T1 (de) Vitamin-d3-derivate.
AR003107A1 (es) Derivados de vitamina d para uso dermatologico, composiciones farmaceuticas que los contienen y procedimiento para la preparacion de dichos derivados.
AR009429A1 (es) Compuestos fenoles y tiofenoles sustituidos utiles como agentes antioxidantes y usos para la fabricacion de medicamentos
ES2133153T3 (es) Nuevos depsipeptidos ciclicos con 18 atomos de anillo, y su empleo para el combate de endoparasitos.
ES2156616T3 (es) (r)-5-bromo-n-(1-etil-4-metilhexahidro-1h-1,4-diazepan-6-il)-2-metoxi-6-metilamino-3-piridincarboxamida, procedimiento para su produccion y composicion medicinal que la contiene.
ES2039719T3 (es) Procedimiento para preparar un agente terapeutico para el tratamiento de la enfermedad de ulcera peptica.
PE20010742A1 (es) COMPOSICION DE UN AGONISTA ß-ADRENERGICO PARA EL TRATAMIENTO DE LA INFERTILIDAD O MEJORA DE LA FERTILIDAD
PA8464301A1 (es) Compuestos derivados del cromeno
ES2123739T3 (es) Nuevos analogos del eburnano, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ES2050303T3 (es) Electrolitos de organoaluminio para la deposicion electrolitica de aluminio de alta pureza.
ES2094048T3 (es) N-acilpirrolidinas y medicamentos para el tratamiento o la prevencion de los desordenes relacionados con la colecistoquinina y la gastrina.
ES2134808T3 (es) Compuestos antivirales oralmente activos.

Legal Events

Date Code Title Description
FX Voluntary withdrawal